Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.

Kantarjian, Hagop M

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug 2009 - 3659-63 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural

1527-7755

10.1200/JCO.2008.18.6999 doi


Benzamides
Cause of Death
Cohort Studies
Cytogenetics
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Fusion Proteins, bcr-abl--genetics
Humans
Imatinib Mesylate
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Neoplasm, Residual--drug therapy
Philadelphia Chromosome
Piperazines--administration & dosage
Polymerase Chain Reaction
Probability
Protein Kinase Inhibitors--administration & dosage
Pyrimidines--administration & dosage
Sensitivity and Specificity
Severity of Illness Index
Survival Analysis
Time Factors
Treatment Outcome